SVB Leerink reaffirmed their market perform rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $21.00 target price on the stock, up from their prior target price of $17.00. Several other equities analysts have also commented on […]